report_id=VIT669 What factors are influencing the growth of the 23 Valent Pneumococcal Polysaccharide Vaccine Market over the forecast period? What is the competitive landscape in Vietnam 23 Valent ...

The 23-valent pneumococcal polysaccharide vaccine (PPSV23) has completed the on-site work for Phase III clinical trials and plans to submit a pre-application for market registration to the National ...

Meanwhile, the launch of new-generation innovative products, including the serum-free rabies vaccine, the 13-valent pneumococcal conjugate vaccine, the quadrivalent meningococcal conjugate vaccine ...

Merck MRK announced that the European Commission (“EC”) has approved its 21-valent pneumococcal conjugate vaccine (“PCV”), Capvaxive, for the prevention of invasive pneumococcal disease ...

The availability of MSD’s vaccine in individual nations will be subject to various factors. Credit: Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its ...

including those in the capsular polysaccharide synthesis locus. Our findings show that the serotype and lineage, and possibly a combination of genomic loci, influence intrinsic pneumococcal growth ...

Participants were randomized to receive a single dose of either one of three lots of CAPVAXIVE or PPSV23 (pneumococcal 23-valent polysaccharide vaccine). Results from the study include ...